The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH and Boehringer Ingelheim International GmbH have signed an agreement providing Boehringer Ingelheim with the option to receive the exclusive rights to a new lead compound for the treatment of schizophrenia to be discovered and developed at the LDC. The novel approach builds on research results from Moritz Rossner and his team at the Max Planck Institute of Experimental Medicine in Göttingen. He will work closely together with th...